Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IVIG 5% for persistent and chronic primary immune thrombocytopenia
CTR20222805Phase 3Completed
- Sponsor
- Hualan Biological Engineering Inc.
- Start
- Oct 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of immune globulin in immune thrombocytopenia (ITP), sponsored by Hualan Biological Engineering Inc. Primary endpoint: Proportion of subjects achieving platelet count response within 7 days. Started Oct 2022; status: completed.
02
Drugs
immune globulin
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on CTR20222805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222805.